| abstract |
This article discloses reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Pharmaceutical compositions including these compounds are also disclosed. Describe methods for using these Btk inhibitors, alone or in combination with other therapeutic agents, to treat autoimmune diseases or conditions, xenoimmune diseases or conditions, cancers including lymphomas, and inflammatory diseases or conditions. |